HSD58 Country Differences in the Clinical Manifestations and Treatment Patterns of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective

Autor: R Jakes, N Kwon, L Huynh, J Hwee, L Baylis, R Alfonso-Cristancho, S Du, A Khanal, MS Duh

Publikováno v: Value in Health. 25:S284-S285

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d97f283f4a6f17a9285b8219d7bad30
https://doi.org/10.1016/j.jval.2022.09.1401

HSD77 Real-World Dosing Patterns of Eculizumab-Naive and Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Ravulizumab in the US

Autor: WY Cheng, J Fishman, M Yenikomshian, M Mahendran, C Kunzweiler, JD Vu, MS Duh

Publikováno v: Value in Health. 25:S493

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::975ae4576ab670cd525713ac59ddda98
https://doi.org/10.1016/j.jval.2022.04.1077

Real-World Healthcare Resource Utilization, Healthcare Costs, and Injurious Falls Among Elderly Patients with Geographic Atrophy.

Autor: Sarda SP; Apellis Pharmaceuticals, Waltham, MA, USA., Germain G; Groupe d'analyse, Ltée, Montreal, Québec, Canada., Mahendran M; Analysis Group, Inc, Boston, MA, USA., Klimek J; Analysis Group, Inc, Boston, MA, USA., Cheng WY; Analysis Group, Inc, Boston, MA, USA., Luo R; Apellis Pharmaceuticals, Waltham, MA, USA., Duh MS; Analysis Group, Inc, Boston, MA, USA.

Publikováno v: Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2024 Nov 09; Vol. 18, pp. 3215-3226. Date of Electronic Publication: 2024 Nov 09 (Print Publication: 2024).

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States.

Autor: Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY. hultcram@mskcc.org., Kleinman D; Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY., Vij R; Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO., Escalante F; Hematology Department, University Hospital of Leon, Leon., Delforge M; Department of Hematology, Catholic University of Leuven, Leuven., Kotowsky N; Value, Evidence and Outcomes, GSK, Upper Providence, PA., Bitetti J; Global Medical Affairs, GSK, Zug., Boytsov N; Value, Evidence and Outcomes, GSK, Upper Providence, PA., Camadoo-O'Byrne L; Real World Study Delivery, GSK, Stevenage., Happ LP; Real World Data Strategy and Partnerships, Value, Evidence and Outcomes, GSK, Collegeville, PA., Germain G; Groupe d'Analyse, Ltee., Montreal, Quebec., Urosevic A; Groupe d'Analyse, Ltee., Montreal, Quebec., Mahendran M; Groupe d'Analyse, Ltee., Montreal, Quebec., Duh MS; Analysis Group, Inc., Boston, MA., Laliberte F; Groupe d'Analyse, Ltee., Montreal, Quebec., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seragnoli', Universita degli Studi di Bologna, Bologna., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Publikováno v: Haematologica [Haematologica] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.

Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer.

Autor: Preston MA; Department of Urology, Brigham and Women's Hospital, Boston, MA. Electronic address: mpreston@bwh.harvard.edu., Ebrahimi R; Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA., Hong A; US Value & Evidence Oncology, Pfizer Inc., New York, NY., Bobbili P; HEOR, Epidemiology, & Market Access, Analysis Group, Boston, MA., Desai R; HEOR, Epidemiology, & Market Access, Analysis Group, Boston, MA., Duh MS; HEOR, Epidemiology, & Market Access, Analysis Group, Boston, MA., Gandhi R; Medical Managed Markets & HEOR, Myovant Sciences Inc., Brisbane, CA., Hanson S; Oncology, Pfizer Inc., New York, NY., Dufour R; Medical Managed Markets & HEOR, Myovant Sciences Inc., Brisbane, CA., Morgans AK; Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA.

Publikováno v: Urologic oncology [Urol Oncol] 2024 Dec; Vol. 42 (12), pp. 447.e1-447.e9. Date of Electronic Publication: 2024 Jul 12.